<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387540</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-17-12</org_study_id>
    <nct_id>NCT03387540</nct_id>
  </id_info>
  <brief_title>Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions</brief_title>
  <acronym>RAFALE</acronym>
  <official_title>Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions Using International Pharmacovigilance Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Cardiometabolism and Nutrition, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events
      (irAEs) on the cardio-vascular system. This study investigates reports of cardio-vascular
      toxicity with treatment including anti-PD1, Anti-PDL-1, and Anti CTLA4 classes using the
      World Health Organization (WHO) database VigiBase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ICIs have dramatically improved clinical outcomes in multiple cancer types and are
      increasingly being tested in earlier disease settings and used in combination. However, irAEs
      can occur. Here the investigators use VigiBase (http://www.vigiaccess.org/), the World Health
      Organization (WHO) database of individual safety case reports, to identify cases of
      cardiovascular adverse drug reaction following treatment with ICIs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 4, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>Cardio-vascular toxicity of ICIs.</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 12/31/2017</time_frame>
    <description>Identification and report of the cardio-vascular toxicity of ICIs. The research includes the report with MedDRA terms: SOC Cardiac Disorders, SOC Vascular Disorders, Sudden death (PT), Cardiac and vascular investigations (excl enzyme tests) (HLGT), Skeletal and cardiac muscle analyses (HLT). Drugs investigated are ICIs: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Causality assessment of reported cardiovascular events according to the WHO system</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 12/31/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the type of cardiotoxicity depending on the category of ICIs</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 12/31/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the duration of treatment when the toxicity happens (role of cumulative dose)</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 12/31/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the drug-drug interactions associated with adverse events</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 12/31/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pathologies (cancer) for which the incriminated drugs have been prescribed</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 12/31/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the population of patients having a cardio-vascular adverse event</measure>
    <time_frame>Case reported in the World Health Organization (WHO) database of individual safety case reports to 12/31/2017</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">104</enrollment>
  <condition>Myocarditis</condition>
  <condition>Cardiac Complication</condition>
  <arm_group>
    <arm_group_label>Myocarditis induced by Immune check point inhibitor</arm_group_label>
    <description>Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICI</intervention_name>
    <description>Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).</description>
    <arm_group_label>Myocarditis induced by Immune check point inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with an ICI for a cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Case reported in the World Health Organization (WHO) database of individual safety
             case reports to 12/31/2017

          -  Adverse event reported were including the MedDRA terms: Cardiac and vascular
             investigations (excl enzyme tests) (HLGT), Vascular disorders (SOC), Skeletal and
             cardiac muscle analyses (HLT), Sudden death (PT), Sudden cardiac death (PT), Cardiac
             disorders (SOC), Cardiac arrhythmias (HLGT), Cardiac disorder signs and symptoms
             (HLGT), Cardiac neoplasms (HLGT), Cardiac valve disorders (HLGT), Congenital cardiac
             disorders (HLGT), Coronary artery disorders (HLGT), Endocardial disorders (HLGT),
             Heart failures (HLGT), Myocardial disorders (HLGT), Pericardial disorders (HLGT)

          -  Patients treated with ICIs included in the ATC: Ipilimumab (L01XC11), Nivolumab
             (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31),
             Atezolizumab (L01XC32).

        Exclusion Criteria:

          -  Chronology not compatible between the drug and the toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM.</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dressler D, Potter H. Molecular mechanisms in genetic recombination. Annu Rev Biochem. 1982;51:727-61. Review.</citation>
    <PMID>6287923</PMID>
  </reference>
  <results_reference>
    <citation>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.</citation>
    <PMID>29536852</PMID>
  </results_reference>
  <results_reference>
    <citation>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply. Lancet. 2018 Aug 4;392(10145):384-385. doi: 10.1016/S0140-6736(18)31556-3.</citation>
    <PMID>30102170</PMID>
  </results_reference>
  <results_reference>
    <citation>Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12.</citation>
    <PMID>30442497</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Anti-PD-1</keyword>
  <keyword>Anti-PD-L1</keyword>
  <keyword>Anti CTLA-4</keyword>
  <keyword>Immune checkpoint inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

